American College of Rheumatology

At 12 weeks, significantly more patients with fibromyalgia receiving the smartphone-based intervention reported clinical improvements compared with the control group.

Findings may be related to a variety of influences including a slower life pace during the pandemic and resilience to prolonged stressors.

Common themes included preferring a standard list of symptoms, active training programs, and the desire for community.

A clinically significant percentage of patients with fibromyalgia in the immediate intervention group had greater improvements in quality of life compared with patients in the delayed cohort.

During this interview segment, Dr. Deodhar described his presentation at the ACR 2023 convergence on longitudinal data regarding bimekizumab for patients with this condition.

Fibromyalgia was 3 times more common among patients with rheumatoid arthritis and Long COVID.

John Botson, MD, discusses his study examining real-world pegloticase plus immunomodulation co-therapy using data from an insurance claims database.

This interview segment with Dr. Mease featured a discussion about data presented at ACR 2023 on guselkumab and patients with psoriatic arthritis.

At month 6, more patients in the AR882 75 mg cohort demonstrated complete resolution of ≥1 tophus compared with patients in the allopurinol cohort.

After a 12-week gap, 5% of patients returned to pegloticase and responded well.

Approximately 10% of patients with gout had a concomitant diagnosis of venous thromboembolism among nearly 800,000 hospitalizations in the US.

This new data from ACR 2023 suggests that the guidelines on a healthy diet predominantly based on plants have been confirmed with regard to incident gout.

At 16 weeks, patients treated with bimekizumab reported greater improvements in both mean spine pain and morning stiffness when compared with placebo. These improvements continued through week 52.

Sustained remission was observed in more patients receiving rituximab and concomitant avacopan compared with those treated with concomitant prednisone.

In this data shown at ACR 2023, the URAT1 inhibitor known as AR882 showed promising phase 2b data for patients with gout.

The most successful outcomes were observed in patients with at least 6 months of pegloticase therapy who promptly began oral therapy within 60 days.

In these phase 3 findings presented at ACR 2023, the safety and efficacy of this drug was proven in ACR20, ACR50, and DAS28-ESR responses.

In this late-breaking research shown at ACR 2023, TLC599 injection led to benefits in patients with a single injection and further benefits with a second.

The study revealed that patients meeting fibromyalgia criteria or displaying fibromyalgia-like symptoms were less likely to meet standardized response criteria with biologic therapy.

This new late-breaking data presented at ACR 2023 was the first clinical evidence indicating efficacy of afimetoran for those with CLE.

Diana Abdueva, PhD, states selecting the right therapy for rheumatoid arthritis is a complex challenge due to both the economic burden of therapies and the trial-and-error process patients often undergo.

New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued TNFi.

The 148-week study evaluated multiple domains of patients with psoriatic arthritis receiving risankizumab treatment, providing insights into patients' improvement over time.

Ryan DeMasi, MD, explained despite the patients' shorter disease duration, they exhibited severe symptoms, prompting a more aggressive early intervention approach using treatment with upadacitinib.

In this research presented at ACR 2023, a connection between antiphospholipid antibodies and a greater potential risk of cardiovascular disease was identified.

Ryan DeMasi, MD, explained the direct and indirect effects of upadacitinib and adalimumab on pain in patients with rheumatoid arthritis.

This segment of Dr. Kivitz’s interview at ACR 2023 featured a discussion about future research on TAK-279 as well as general outlook on the field for psoriatic arthritis.

During this interview, Dr. Kivitz explained the background and key findings of his team’s research on TAK-279, a selective oral TYK2 inhibitor.

Patients with PsA in the self-reported racial and ethnic minority were less likely to be diagnosed within 12 months of symptom onset and were more frequently uninsured compared with White patients .

This data represented the first-ever research presented at ACR on both fractures and calcium pyrophosphate deposition disease.